Research programme: antibody-drug conjugates - Sorrento Therapeutics
Alternative Names: AfDCs - Sorrento Therapeutics; Antibody-formulated drug conjugates - Sorrento Therapeutics; STI-0602; ZV05 ADCs - Sorrento TherapeuticsLatest Information Update: 28 Jul 2023
At a glance
- Originator Sorrento Therapeutics
- Class Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Cell death stimulants; Proto-oncogene protein c-met modulators; Vascular endothelial growth factor receptor-2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Haematological malignancies; Non-small cell lung cancer
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 28 May 2020 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
- 24 Mar 2020 Sorrento Therapeutics plans a phase I trial for Amyloidosis (Parenteral) in August 2020 (NCT04316442)